Skip to main content
APGE
NASDAQ Life Sciences

Apogee的Zumilokibart在特应性皮炎的52周第2期试验中呈现出强劲的结果，显示出每季度/半年给药的持久疗效

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
9
Price
$79
Mkt Cap
$4.589B
52W Low
$26.2
52W High
$84.56
Market data snapshot near publication time

summarizeSummary

Apogee Therapeutics宣布其Zumilokibart（APG777）在中度至重度特应性皮炎的第2期APEX临床试验Part A中获得了高度积极的52周维护数据。结果表明，维护和加深的反应持久，75-85%的患者在每3-6个月给药时维持了EASI-75，78-86%的患者维持了vIGA 0/1。这些数据是Apogee领先候选药物的一个重要去风险事件，凸显了其潜在的最佳治疗方案特征，原因是其给药频率远低于当前治疗方法。这种强大的疗效和方便的给药安排可能会对患者产生变革性的影响，并提供了实质性的竞争优势。投资者现在将关注即将到来的APEX Part B 16周诱导读数的结果，该结果将在2026年第二季度公布，以及计划于2026年下半年启动的第3期试验。

在该公告发布时，APGE的交易价格为$79.00，交易所为NASDAQ，所属行业为Life Sciences，市值约为$45.9亿。 52周交易区间为$26.20至$84.56。 这则新闻被评估为积极市场情绪，重要性评分为9/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed APGE - Latest Insights

APGE
Mar 25, 2026, 4:53 PM EDT
Source: Wiseek News
Importance Score:
9
$377.4M Equity Offering Finalized by Apogee Therapeutics, Underwriters Exercise Full Option
Sentiment: Neutral
View Wiseek Article
APGE
Mar 25, 2026, 4:44 PM EDT
Filing Type: 8-K
Importance Score:
8
Apogee Therapeutics Finalizes $402.5M Public Offering at $70.00/Share
Sentiment: Negative
View Wiseek Article
APGE
Mar 25, 2026, 4:40 PM EDT
Filing Type: 424B5
Importance Score:
8
Apogee Therapeutics Prices $350M Public Offering at $70.00/Share Following Positive Clinical Data
Sentiment: Neutral
View Wiseek Article
APGE
Mar 24, 2026, 9:54 PM EDT
Source: Reuters
Importance Score:
8
Apogee Therapeutics Prices $350M Offering at $70/Share Following Positive Trial Data
Sentiment: Neutral
View Wiseek Article
APGE
Mar 23, 2026, 4:28 PM EDT
Filing Type: 424B5
Importance Score:
8
Apogee Therapeutics Launches $300M Public Offering Following Positive Phase 2 Data
Sentiment: Neutral
View Wiseek Article
APGE
Mar 23, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Apogee Therapeutics Proposes $300M Public Offering Following Positive Clinical Data
Sentiment: Neutral
View Wiseek Article
APGE
Mar 23, 2026, 6:36 AM EDT
Filing Type: 8-K
Importance Score:
9
Apogee Therapeutics Reports Strong 52-Week Phase 2 Data for Zumilokibart in Atopic Dermatitis
Sentiment: Positive
View Wiseek Article
APGE
Mar 23, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
9
Apogee's Zumilokibart Delivers Strong 52-Week Phase 2 Data in Atopic Dermatitis, Showing Durable Efficacy with Quarterly/Biannual Dosing
Sentiment: Positive
View Wiseek Article
APGE
Mar 02, 2026, 7:25 AM EST
Source: Unknown
Importance Score:
7
Apogee Therapeutics Reports $0 Revenue, $(4.22) EPS in 2025 10-K Amid Heavy R&D Investment
Sentiment: Negative
View Wiseek Article
APGE
Mar 02, 2026, 7:20 AM EST
Filing Type: 10-K
Importance Score:
9
Apogee Therapeutics Reports Strong Clinical Progress for Lead Candidate, Secures Long Runway into 2028
Sentiment: Positive
View Wiseek Article